Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma.

Yawei SunShuai WangXingwei ZhangZhuhao WuZihui LiZhuang DingXiaofeng HuangSheng ChenYue JingXiaoxin ZhangLiang DingYuxian SongGuowen SunYanhong Ni

Published in: Biomolecules (2021)

PLOD2 was a poor prognostic biomarker for OSCC patients and may affect the metastasis of OSCC through EMT pathway. These findings might shed novel sights for future research in PLOD2 targeted OSCC therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
epithelial mesenchymal transition
stem cells
cancer therapy
current status
patient reported outcomes
signaling pathway